Coagulation factor XIII deficiency
Authors:
- V. IvaskeviciusVIV. Ivaskevicius
- A. ThomasATA. Thomas
- J. OldenburgJOJ. Oldenburg
- A. BiswasA. Biswas
- 1 January 2014
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 34 (02) , 160-166
Abstract
Summary: The plasma circulating zymogenic coagulation factor XIII (FXIII) is a protransglutaminase, which upon activation by thrombin and calcium cross-links preformed fibrin clots/fibrinolytic inhibitors making them mechanically stable and less susceptible to fibrinolysis. The zymogenic plasma FXIII molecule is a heterotetramer composed of two catalytic FXIII-A and two protective FXIII-B subunits. Factor XIII deficiency resulting from inherited or acquired causes can result in pathological bleeding episodes. A diverse spectrum of mutations have been reported in the F13A1 and F13B genes which cause inherited severe FXIII deficiency. The inherited severe FXIII deficiency, which is a rare coagulation disorder with a prevalence of 1 in 4 million has been the prime focus of clinical and genetic investigations owing to the severity of the bleeding phenotype associated with it. Recently however, with a growing understanding into the pleiotropic roles of FXIII, the fairly frequent milder form of FXIII deficiency caused by heterozygous mutations has become one of the subjects of investigative research. The acquired form of FXIII deficiency is usually caused by generation of autoantibodies or hyperconsumption in other disease states such as disseminated intravascular coagulation. Here, we update the knowledge about the pathophysiology of factor XIII deficiency and its therapeutic options.Keywords
This publication has 64 references indexed in Scilit:
- New developments in the management of congenital Factor XIII deficiencyJournal of Blood Medicine, 2013
- A common F13A1 intron 1 variant IVS1+12(A) is associated with mild FXIII deficiency in Caucasian populationAnnals of Hematology, 2013
- The antifibrinolytic function of factor XIII is exclusively expressed through α2-antiplasmin cross-linkingBlood, 2011
- Hemorrhagic Acquired Factor XIII (13) Deficiency and Acquired Hemorrhaphilia 13 RevisitedSeminars in Thrombosis and Hemostasis, 2011
- Homozygous intronic mutation leading to inefficient transcription combined with a novel frameshift mutation in F13A1 gene causes FXIII deficiencyJournal of Human Genetics, 2011
- Factor XIII: novel structural and functional aspectsJournal of Thrombosis and Haemostasis, 2011
- Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and functionHaematologica, 2010
- Natural selection and the molecular basis of electrophoretic variation at the coagulation F13B locusEuropean Journal of Human Genetics, 2008
- Factor XIII: recommended terms and abbreviationsJournal of Thrombosis and Haemostasis, 2007
- FACTOR XIII DEFICIENCYBritish Journal of Haematology, 1999